Nutra Pharma Announces First Manufacturing Release of Nyloxin Rx, a Prescription Treatment for Chronic Pain
Posted May 25 2010 12:00am
May 25, 2010
Coral Springs, FL (MARKETWIRE via COMTEX) -- Nutra Pharma Corp, a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has completed manufacturing the first batch of its prescription pain reliever, Nyloxin Rx, and has successfully released it for initial marketing-related distribution within the United States.
"We are pleased to be announcing the rollout of the Company's first prescription drug, Nyloxin Rx," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "As we move forward with the launch of Nyloxin Rx, we continue to seek partnerships with established U.S. and international distributors to assist us with ongoing marketing to physician offices, hospitals and medical clinics," he added.
Nyloxin Rx is a prescription pain reliever clinically proven to treat Stage 3 (severe) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one's ability to fully function.
The drug, which was developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating angina pectoris, angina faucium, back pain, headaches, joint pain, migraines, neck pain, neuralgia, ovarian pain, and painful periods and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Currently, physicians can request samples of Nyloxin Rx by visiting the Healthcare Providers section of the Nyloxin website: http://www.Nyloxin.com/healthcare_providers.
About Nutra Pharma Corp. Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases.
The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process.
Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Cobroxin, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Both Cobroxin and Nyloxin were developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm.